ReviewAmerican journal of clinical oncology2019
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
Review in American journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 51 citations in OpenAlex.
- Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study.Asia-Pacific journal of clinical oncology · 2021Trial
- Real-world effectiveness and safety of radium-223 therapy in castration-resistant prostate cancer with bone metastases.Asian journal of andrology · 2026Article
- Radium - from discovery to the present day - narrative review.Clinical and experimental medicine · 2026Review
- Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Observational
- Development and Dosimetric Characterization of an In Vitro Benchtop Americium 241 Alpha Irradiator Platform.International journal of radiation oncology, biology, physics · 2026Article
- Ultrasmall AuExploration (Beijing, China) · 2026Article
- Preclinical Evaluation of Radium-223 and Immune Checkpoint Inhibitors Using an Immune-Competent Model of Prostate Cancer Bone Metastases.Precision oncology · 2026Article
- Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction.International journal of molecular sciences · 2026Review
- Evaluation of cumulative absorbed dose in tumors of various sizes regardingAnnals of nuclear medicine · 2026Article
- Comparison of imaging-based bone marrow dosimetry methodologies and their dose-effect relationships in [EJNMMI physics · 2025Article
- Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated withDiagnostics (Basel, Switzerland) · 2025Article
- Chest Pain as a Symptom of Early-Onset Metastatic Prostate Cancer: Exploring the Role of Screening.Cureus · 2025Article
- Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer.Investigational new drugs · 2024Article
- Radiotheranostics in advanced prostate cancer: Current and future directions.Prostate cancer and prostatic diseases · 2024Review
- BeTTer Outcomes Workgroup Health Quality Initiative to optimize bone health for prostate cancer patients in the British Columbia Cancer System.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Article
- Prostate cancer bone metastases biology and clinical management (Review).Oncology letters · 2023Review
- Radiochemical Quality Control Methods for Radium-223 and Thorium-227 Radiotherapies.Cancer biotherapy & radiopharmaceuticals · 2023Article
- Impact of DNA damage repair alterations on prostate cancer progression and metastasis.Frontiers in oncology · 2023Review
- Factors Influencing Outcome Post-Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges.World journal of nuclear medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone metastases are common in men with metastatic castrate-resistant prostate cancer (mCRPC), occurring in 30% of patients within 2 years of castrate resistance and in >90% of patients over the disease course. There are 6 US Food and Drug Administration-approved therapies for mCRPC with demonstrated survival benefit. Of these, only radium-223 (Ra-223) specifically targets bone metastases, delays development of skeletal-related events, and improves survival. This review discusses key data from the ALSYMPCA trial, which contributed to the approval of Ra-223. Data from other trials are highlighted to provide further insight into which patients might benefit from Ra-223. Special patient populations are described, as well as other considerations for the administration of Ra-223. Finally, ongoing trials of Ra-223 combined with other therapies for mCRPC are discussed. These include combining Ra-223 with sipuleucel-T or immunooncology agents, to enhance immune responses, and trials in mildly symptomatic or asymptomatic patients. To date, the optimal timing, sequence, and combinations of Ra-223 with other agents are yet to be determined. The goals of this review are to provide insight into practical aspects of patient selection for Ra-223 treatment and to discuss key therapeutic strategies using the 6 approved mCRPC agents in patients with bone metastases. Results from ongoing trials should help guide the practitioner in using Ra-223 in patients with mCRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.